Gut bacteria transplants from two donor groups for ulcerative colitis
Compares stool transplants from Dai and Han donors in adults with ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors
Key facts
- Where
- Kunming, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-60 with left-sided ulcerative colitis who are treated only with mesalazine. They receive fecal transplants from Han or Dai donors.
- Age
- 18-60 years
- Sex
- All sexes can join.
- Disease stage
- Left-sided ulcerative colitis with a baseline Mayo score of 3-10. People in clinical remission cannot join.
- Earlier treatment
- Treated only with mesalazine before and during the study.
Main reasons for not taking part
- Pregnancy or planned pregnancy in the near future
- Clinical remission (Mayo score ≤2 with no individual subscore >1)
- History of toxic megacolon, perianal disease, or intestinal surgery
- Severe heart, lung or kidney disease, or cancer at the same time
- Development of other diseases that confuse the first diagnosis during the study
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07814456, who can take part
Where in China
- Kunming Medical University First Affiliated HospitalKunming, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- First Affiliated Hospital of Kunming Medical University
- Trial code
- NCT07814456
- Record updated
- 15 September 2026
- Original description
This study is a randomized clinical trial evaluating fecal microbiota transplantation (FMT) for ulcerative colitis (UC) using healthy donors from two ethnic groups in Yunnan, China. UC is a chronic inflammatory bowel disease causing colon inflammation and ulcers. FMT transfers gut bacteria from a healthy donor to a patient to restore healthy intestinal microbiota.Read full original descriptionShow less
Fecal Microbiota Transplantation for Ulcerative Colitis Using Healthy Donors From Yunnan Dai and Han Nationalities: A Randomized Study to Screen Core Metabolites and Key Microbiota
This study is a randomized clinical trial evaluating fecal microbiota transplantation (FMT) for ulcerative colitis (UC) using healthy donors from two ethnic groups in Yunnan, China. UC is a chronic inflammatory bowel disease causing colon inflammation and ulcers. FMT transfers gut bacteria from a healthy donor to a patient to restore healthy intestinal microbiota.
Previous research suggested that FMT using donors from the Dai ethnic group (a minority nationality in Yunnan with special dietary habits) may achieve better results than Han Chinese donors for UC. This study aims to confirm this finding and understand why.
The investigators will recruit 200 UC patients (ages 18-60) and randomly assign them to two groups (100 each). One group will receive FMT from healthy Han donors; the other from healthy Dai donors. Patients will receive three FMT infusions via endoscopic intestinal tubing. Treatment effects will be assessed at 12 weeks using clinical scores (Mayo score), endoscopic scores (MES), inflammatory markers (fecal calprotectin, CRP, ESR), and intestinal barrier function tests.
Stool samples will also be analyzed using metabolomics and metagenomics to identify key gut bacteria and metabolites linked to better outcomes, and laboratory experiments will be performed to verify how they reduce intestinal inflammation.
The goal is to identify optimal donor characteristics for FMT in UC and uncover mechanisms that may lead to more personalized microbiota therapies.
Inclusion: Age 18-60 years; Diagnosed with ulcerative colitis (left-sided colitis) according to ECCO guidelines and Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023 Xi'an); Baseline Mayo score 3-10; Treated only with mesalazine before and during the study to exclude drug interference.
Exclusion: Concurrent severe cardiac, pulmonary, or renal disease, or malignancy; Development of diseases different from or confounding the initial diagnosis during the study; History of toxic megacolon, perianal disease, or intestinal surgery; Pregnancy or planned pregnancy in the near future; Patients in clinical remission (Mayo score ≤2 with no individual subscore >1).